AEterna Zentaris: ZEN-019 suppresses testosterone in rat model

By Lisa Kerner

Charlotte, N.C., June 27 - AEterna Zentaris said that a single, orally administered 20 mg/kg dose of ZEN-019, an oral LHRH antagonist peptidomimetic, suppressed plasma testosterone levels for up to 12 hours in rats.

In addition, a repeat dosing of ZEN-019 increased the suppression time without accumulating in the plasma.

The data was presented in an abstract during the 2006 Annual Meeting of the Endocrine Society in Boston.

ZEN-019 is part of AEterna Zentaris' drug development program, which includes cetrorelix, marketed for in vitro fertilization under the brand name Cetrotide and in late-stage clinical development for benign prostate hyperplasia (BPH) and endometriosis, as well as ozarelix, being studied in prostate cancer and BPH.

AEterna Zentaris is a Quebec City biopharmaceutical company focused on oncology and endocrine therapy.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.